Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs ...
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
- Associated Therapies
- -
Can MRI Evaluate Beta-blocker Response in Portal Hypertension?
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 68
- Registration Number
- NCT03114813
- Locations
- 🇬🇧
NIHR Nottingham Biomedical Research Centre, Nottingham, Nottinghamshire, United Kingdom
🇬🇧University of Nottingham, Nottingham, United Kingdom
Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 330
- Registration Number
- NCT03069339
- Locations
- 🇮🇳
Institute of liver and Biliary Sciences, New Delhi, Delhi, India
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 134
- Registration Number
- NCT02993198
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 50
- Registration Number
- NCT02975323
- Locations
- 🇵🇰
Aga Khan University,, Karachi, Sind, Pakistan
Effect of Carvedilol on Exercise Performance in Fontan Patients
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02946892
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT02944201
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Changqing Yang
- Target Recruit Count
- 100
- Registration Number
- NCT02925975
- Locations
- 🇨🇳
Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Changqing Yang
- Target Recruit Count
- 96
- Registration Number
- NCT02907749
- Locations
- 🇨🇳
Shanghai Tongji Hospital, Tongji University, Shanghai, Shanghai, China
Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 100
- Registration Number
- NCT02809820
- Locations
- 🇮🇹
Federico II University of Naples, Naples, Italy
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
- Conditions
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 196
- Registration Number
- NCT02717507
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States
🇺🇸Saint Mary's Hospital, West Palm Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.